Adjuvant Treatment of Resected Node-Positive Melanoma With Immune Checkpoint Inhibitors

Download this expert-authored slideset from a live symposium reviewing best practices in the use of adjuvant immune checkpoint inhibitor therapy for advanced melanoma.
Michael Atkins Headshot
Michael B. Atkins, MD
Ahmad Tarhini, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.45 MB
Released: March 29, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck & Co., Inc.

Related Content

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

AMBER trial of cobolimab and dostarlimab shows manageable safety in advanced solid tumors and promising activity in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 20, 2022

CheckMate 067 7.5-year follow-up with nivolumab + ipilimumab in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings